KATHRYN THRAILKILL

Summary

Affiliation: University of Arkansas for Medical Sciences
Country: USA

Publications

  1. ncbi Determinants of undercarboxylated and carboxylated osteocalcin concentrations in type 1 diabetes
    K M Thrailkill
    Department of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children s Hospital Research Institute, Little Rock, AR 72205, USA
    Osteoporos Int 23:1799-806. 2012
  2. ncbi Palmitate and insulin synergistically induce IL-6 expression in human monocytes
    Robert C Bunn
    Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
    Cardiovasc Diabetol 9:73. 2010
  3. ncbi Insulin pump therapy started at the time of diagnosis: effects on glycemic control and pancreatic β-cell function in type 1 diabetes
    Kathryn M Thrailkill
    Department of Pediatrics, University of Arkansas for Medical Sciences, Arkansas Children s Hospital Research Institute, Little Rock, Arkansas 72202, USA
    Diabetes Technol Ther 13:1023-30. 2011
  4. ncbi Disease and gender-specific dysregulation of NGAL and MMP-9 in type 1 diabetes mellitus
    Kathryn M Thrailkill
    Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR, 72202, USA
    Endocrine 37:336-43. 2010
  5. ncbi Enhanced excretion of vitamin D binding protein in type 1 diabetes: a role in vitamin D deficiency?
    Kathryn M Thrailkill
    Department of Pediatrics, Arkansas Children s Hospital, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72202, USA
    J Clin Endocrinol Metab 96:142-9. 2011
  6. ncbi Microalbuminuria in type 1 diabetes is associated with enhanced excretion of the endocytic multiligand receptors megalin and cubilin
    Kathryn M Thrailkill
    Department of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children s Hospital Research Institute, Little Rock, Arkansas, USA
    Diabetes Care 32:1266-8. 2009
  7. ncbi Matrix metalloproteinases: their potential role in the pathogenesis of diabetic nephropathy
    Kathryn M Thrailkill
    Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR 72202, USA
    Endocrine 35:1-10. 2009
  8. ncbi Matrix metalloproteinase-2 dysregulation in type 1 diabetes
    Kathryn M Thrailkill
    Department of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children s Hospital Research Institute, Little Rock, Arkansas 72202, USA
    Diabetes Care 30:2321-6. 2007
  9. ncbi Bone formation is impaired in a model of type 1 diabetes
    Kathryn M Thrailkill
    Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Diabetes 54:2875-81. 2005
  10. ncbi Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues
    Kathryn M Thrailkill
    Department of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children s Hospital, 800 Marshall St, Springer Bldg, Mail Slot 512 6, Little Rock, AR 72202, USA
    Am J Physiol Endocrinol Metab 289:E735-45. 2005

Research Grants

  1. Matrix metalloproteinases and diabetic nephropathy
    KATHRYN THRAILKILL; Fiscal Year: 2005

Collaborators

Detail Information

Publications22

  1. ncbi Determinants of undercarboxylated and carboxylated osteocalcin concentrations in type 1 diabetes
    K M Thrailkill
    Department of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children s Hospital Research Institute, Little Rock, AR 72205, USA
    Osteoporos Int 23:1799-806. 2012
    ..UC-OC and GLA-OC concentrations were similar between groups; however, in T1D, UC-OC correlated positively with markers of insulin exposure, either endogenously produced or exogenously administered...
  2. ncbi Palmitate and insulin synergistically induce IL-6 expression in human monocytes
    Robert C Bunn
    Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
    Cardiovasc Diabetol 9:73. 2010
    ....
  3. ncbi Insulin pump therapy started at the time of diagnosis: effects on glycemic control and pancreatic β-cell function in type 1 diabetes
    Kathryn M Thrailkill
    Department of Pediatrics, University of Arkansas for Medical Sciences, Arkansas Children s Hospital Research Institute, Little Rock, Arkansas 72202, USA
    Diabetes Technol Ther 13:1023-30. 2011
    ....
  4. ncbi Disease and gender-specific dysregulation of NGAL and MMP-9 in type 1 diabetes mellitus
    Kathryn M Thrailkill
    Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR, 72202, USA
    Endocrine 37:336-43. 2010
    ....
  5. ncbi Enhanced excretion of vitamin D binding protein in type 1 diabetes: a role in vitamin D deficiency?
    Kathryn M Thrailkill
    Department of Pediatrics, Arkansas Children s Hospital, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72202, USA
    J Clin Endocrinol Metab 96:142-9. 2011
    ..Vitamin D deficiency is an increasingly recognized comorbidity in patients with both type 1 (T1D) and type 2 diabetes, particularly associated with the presence of diabetic nephropathy...
  6. ncbi Microalbuminuria in type 1 diabetes is associated with enhanced excretion of the endocytic multiligand receptors megalin and cubilin
    Kathryn M Thrailkill
    Department of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children s Hospital Research Institute, Little Rock, Arkansas, USA
    Diabetes Care 32:1266-8. 2009
    ..Our objective was to identify proteins in the urine of individuals with type 1 diabetes and microalbuminuria that might implicate a mechanistic pathway operative in proteinuria...
  7. ncbi Matrix metalloproteinases: their potential role in the pathogenesis of diabetic nephropathy
    Kathryn M Thrailkill
    Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR 72202, USA
    Endocrine 35:1-10. 2009
    ....
  8. ncbi Matrix metalloproteinase-2 dysregulation in type 1 diabetes
    Kathryn M Thrailkill
    Department of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children s Hospital Research Institute, Little Rock, Arkansas 72202, USA
    Diabetes Care 30:2321-6. 2007
    ..Our objective was to explore whether systemic MMP-2 dysregulation could be demonstrated in type 1 diabetes and to determine how MMP-2 concentration relates to disease status...
  9. ncbi Bone formation is impaired in a model of type 1 diabetes
    Kathryn M Thrailkill
    Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Diabetes 54:2875-81. 2005
    ..These studies demonstrate that bone formation during DO is impaired in a model of type 1 diabetes and preserved by systemic insulin administration...
  10. ncbi Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues
    Kathryn M Thrailkill
    Department of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children s Hospital, 800 Marshall St, Springer Bldg, Mail Slot 512 6, Little Rock, AR 72202, USA
    Am J Physiol Endocrinol Metab 289:E735-45. 2005
    ..In so doing, we present evidence that insulin, acting as an anabolic agent in bone, can preserve and increase bone density and bone strength, presumably through direct and/or indirect effects on bone formation...
  11. ncbi Physiological matrix metalloproteinase concentrations in serum during childhood and adolescence, using Luminex Multiplex technology
    Kathryn M Thrailkill
    Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR 72202, USA
    Clin Chem Lab Med 43:1392-9. 2005
    ..76; p<0.01). MMP results obtained by Fluorokin MultiAnalyte Profiling methods correlated well with conventional ELISA methods and use of this technology provided several advantages over ELISA...
  12. ncbi Stimulant medication use and response to growth hormone therapy: an NCGS database analysis
    J Paul Frindik
    University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
    Horm Res 72:160-6. 2009
    ..Determine (1) frequency of attention-deficit hyperactivity disorder (ADHD) treatment and (2) growth responses in growth hormone (GH)-treated children who are receiving ADHD medication versus GH alone...
  13. ncbi A novel rat model for the study of deficits in bone formation in type-2 diabetes
    Zhendong Liu
    Laboratory for Limb Regeneration Research, Arkansas Children s Hospital Research Institute, Little Rock, AR, USA
    Acta Orthop 78:46-55. 2007
    ..Using Zucker Diabetic Fatty (ZDF) rats (a model of type-2 diabetes) for tibial distraction osteogenesis (DO), we hypothesized that bone formation within the distraction gap would be impaired...
  14. ncbi SomatoKine: is there a use in treating growth disorders?
    Stephen F Kemp
    University of Arkansas for Medical Sciences, Arkansas Children s Hospital, 800 Marshall Street, Little Rock, AR 72202 3591, USA
    Curr Opin Investig Drugs 6:373-7. 2005
    ..SomatoKine appears to have a longer half-life in patients with GHIS than unbound IGF-I and fewer adverse events (including hypoglycemia) have been reported when administered to patients with diabetes...
  15. ncbi Regulation of insulin-like growth factor (IGF)-I action by matrix metalloproteinase-3 involves selective disruption of IGF-I/IGF-binding protein-3 complexes
    John L Fowlkes
    Division of Pediatric Endocrinology and Diabetes, University of Arkansas for Medical Sciences, Arkansas Children s Hospital, Arkansas Children s Hospital Research Institute, 800 Marshall Street, Slot 512 6, Little Rock, AR 72202, USA
    Endocrinology 145:620-6. 2004
    ....
  16. ncbi Restoration of regenerative osteoblastogenesis in aged mice: modulation of TNF
    Elizabeth C Wahl
    Arkansas Children s Hospital Research Institute, Little Rock, AR 72202, USA
    J Bone Miner Res 25:114-23. 2010
    ..It has been hypothesized recently that TNF antagonists may represent novel anabolic agents, and we believe that the data presented here represent a successful test of this hypothesis...
  17. ncbi Investigational agents for the treatment of growth hormone-insensitivity syndrome
    Stephen F Kemp
    University of Arkansas for Medical Sciences, Arkansas Children s Hospital, Little Rock, AR 72202 3591, USA
    Expert Opin Investig Drugs 15:409-15. 2006
    ..There are no studies comparing the efficacy of mecasermin with mecasermin rinfabate; both drugs have been shown to be effective but cannot be differentiated in terms of efficacy...
  18. ncbi Efficacy and safety of mecasermin rinfabate
    Stephen F Kemp
    University of Arkansas for Medical Sciences, Arkansas Children s Hospital, Little Rock, AR 72202 3591, USA
    Expert Opin Biol Ther 6:533-8. 2006
    ....
  19. ncbi Runt-related transcription factor 2 (RUNX2) and RUNX2-related osteogenic genes are down-regulated throughout osteogenesis in type 1 diabetes mellitus
    John L Fowlkes
    Arkansas Children s Hospital, 800 Marshall Street, Little Rock, AR 72202, USA
    Endocrinology 149:1697-704. 2008
    ..Together, these data demonstrate that insulin and/or glycemic status can regulate osteogenesis in vivo, and systemic insulin therapy can, in large part, rescue the diabetic bone phenotype at the tissue and molecular level...
  20. ncbi Effects of systemic and local administration of recombinant human IGF-I (rhIGF-I) on de novo bone formation in an aged mouse model
    John L Fowlkes
    Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
    J Bone Miner Res 21:1359-66. 2006
    ..Local and systemic rhIGF-I treatment increased new bone formation. However, only systemic delivery produced measurable concentrations of rhIGF-I in the circulation...
  21. ncbi GAD-alum immunotherapy in Type 1 diabetes mellitus
    Alba E Morales
    Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR 72202, USA
    Immunotherapy 3:323-32. 2011
    ..Hence, clinical trials are ongoing to examine the efficacy and safety of GAD-alum immunotherapy in patients with autoimmune-mediated forms of diabetes, including Type 1 diabetes and latent autoimmune diabetes in adults...
  22. ncbi Direct bone formation during distraction osteogenesis does not require TNFalpha receptors and elevated serum TNFalpha fails to inhibit bone formation in TNFR1 deficient mice
    Elizabeth C Wahl
    Laboratory for Limb Regeneration Research, Arkansas Children s Hospital Research Institute, Little Rock, AR, USA
    Bone 46:410-7. 2010
    ..We conclude that exogenous rmTNF and/or endogenous TNF act to inhibit new bone formation during DO by signaling primarily through TNFR1...

Research Grants4

  1. Matrix metalloproteinases and diabetic nephropathy
    KATHRYN THRAILKILL; Fiscal Year: 2005
    ..We anticipate that this study will provide preliminary evidence to establish a link between dysregulation of MMP activity and the pathogenesis of nephropathy in type 1 DM. ..